HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report report published on Friday morning,Benzinga reports. HC Wainwright curr… [+4593 chars]...
Read moreStockNews.com assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the bio… [+4366 chars]...
Read moreStockNews.com started coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research report released on Saturday. The firm issued a sell rating on the biopharmaceutical compa… [+4295 chars]...
Read moreStockNews.com started coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research note published on Friday. The firm issued a sell rating on the biopharmaceutical company’… [+4256 chars]...
Read moreCharles Schwab Investment Management Inc. lowered its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 16.0% during the 4th quarter, Holdings Channel.com reports. The institution… [+4660 chars]...
Read moreVirtu Financial LLC purchased a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securitie… [+4860 chars]...
Read more